🔍 Advertising Regulation in Japan (Promotional Material Review) and Artificial Intelligence JP/EN
Ethics · Regulation · Technology — Pharma Practice Notes
Independent chapter·10 episodes + template library·Published June 7, 2026

Production Quality Management— Quality assurance for client-commissioned materials — guaranteeing full regulatory compliance from concept to signed delivery

An independent chapter designed for organizations that produce pharma promotional and educational materials on behalf of pharmaceutical clients. From the moment a client's initial concept is received, the framework here guarantees full compliance with Japan's Advertising Appropriateness Standards, the Sales-Information-Provision Activity Guideline (HanteiG), and the JPMA Creation Guidelines — building a review system that eliminates "potential doubt" before it can arise. After draft completion, AI prompts from this site perform exhaustive cross-checks for regulatory gaps. QC and QA Standard Operating Procedures are mandatory; on client delivery, QC/QA quality records signed by both the executing reviewer and the responsible manager are submitted to the client. This chapter publishes ten topics that compose the full pipeline, plus an evolving library of AI prompts, algorithms, system flows, and check-table templates.

01Why This Is Designed as an Independent Chapter

Today's standard practice is that pharma promotional and educational materials should clear regulatory compliance on the production side, before they ever reach the pharmaceutical client's internal review (the work covered in our "Material Review" series). Rather than discovering violations or questionable elements during the client's internal review, the production side must eliminate every potential doubt first — so internal reviewers can focus on constructive judgment instead of defensive correction. That is the starting point of this chapter.

Where the Material Review series presents the client (commissioner) viewpoint, this chapter presents the production side viewpoint on how quality is built in. The two are mirror images, structurally complementary.

02The Four Pillars

Pillar 01

Complete Regulatory Conformance

A mechanism that mechanically maps commissioned materials against the intersection of the Advertising Appropriateness Standards, HanteiG, the JPMA Creation Guidelines, and Pharmaceutical Act §§66–68. Mapping tables eliminate "any possible doubt."

Pillar 02

Multi-Angle AI Review

After draft completion, an AI prompt library (including this site's Prompt Commons) catches efficacy overreach, safety-balance gaps, citation issues, visual balance, and implicit claims. AI fills the gaps that human reviewers miss.

Pillar 03

QC / QA Standard Operating Procedures

The three-stage flow — production → QC (quality check) → QA (regulatory assurance) — is captured in formal SOPs. Personalization is removed; reproducibility is built in: anyone executing the procedure gets the same result.

Pillar 04

Signed Delivery

At delivery, quality records bearing four signatures — QC executor, QC manager, QA executor, QA manager — are submitted to the client. Both production-side and client-side retain the audit trail of judgment.

03The 10-Episode Structure

Part 1 — Designing the Framework
Part 2 — Regulatory Mapping and the Review System
Part 3 — AI-Prompt-Driven Regulatory Review
Part 4 — QC / QA SOPs and Templates
Part 5 — Delivery and Governance

04Appendices — AI Prompts · Algorithms · System Flows · Check Tables

The chapter publishes the following appendices on an ongoing basis, both embedded into volume articles and as standalone template pages.

Disclaimer

Use of This Chapter and Allocation of Responsibility

The documents, AI prompts, algorithms, system flows, check tables, SOP templates, and all other deliverables published in this chapter (collectively, "the Materials") are reference content for informational purposes. Production-side operators, pharmaceutical companies, and any other entity wishing to use the Materials are permitted to use, customize, and internalize them at their own judgment and responsibility.

However, with respect to any and all consequences, damages, legal liability, regulatory actions, client disputes, third-party claims, or any other adverse outcomes arising from or related to the use of, reference to, or application of the Materials, Advertising Regulation in Japan (Promotional Material Review) and Artificial Intelligence, the authors of this site, and related parties bear no responsibility whatsoever.

The Materials do not guarantee that they reflect the permanent latest version of regulations, statutes, or industry norms. Pharmaceutical regulations (Pharmaceutical Act, Advertising Appropriateness Standards, HanteiG, JPMA Creation Guidelines, and others) are periodically revised. Confirmation of the current version and final regulatory-compliance judgment rest with each entity using the Materials.

The Materials are not a substitute for legal counsel, legal advice, compliance services, or consulting services. For specific judgments regarding the regulatory compliance of commissioned materials, consult internal compliance and legal teams, or external specialists (attorneys, pharmaceutical regulatory consultants, etc.).

← Back to Home